Philips and Indica Labs Team to Accelerate Cancer Research through Advanced Image Analysis

Best, Netherlands and New Mexico, USA – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will further support oncology researchers’ efforts to analyze pathology samples by offering advanced image analysis algorithms from Indica Labs, Inc. as part of its Digital Pathology Solutions offerings. The collaboration will allow pathology researchers to apply intelligent algorithms to digitized pathology slides, which may enhance their ability to detect, process and extract information from tissue samples than currently possible using a conventional microscope.

With  more than 500,000 deaths expected in 2014, cancer is the second most common cause of death in the U.S. As the current cancer care process is often complex, inefficient and ineffective, there is a growing need to empower pathologists with quantitative data to inform personalized approaches and enable new cancer treatments.

“Digital pathology is the stepping stone to unlock the huge potential of data mining,” says Perry van Rijsingen, General Manager of Philips Digital Pathology Solutions. “More information from tissue samples could bring new insights in cancer care that support personal treatment, and ultimately will save patients’ lives.”

Image analysis, when based on high-quality digital images, has been shown to provide objective data sets for decision support. By using the combined Philips Digital Pathology Solution and Indica’s HALO™ image analysis platform, researchers will benefit from a streamlined image analysis workflow and improved productivity. Additionally, they will be able to extract more thorough information from tissue samples, enabling more insightful analysis than possible today – all while generating those results in a matter of hours or even minutes versus days.

“Digital pathology offers significant opportunity to arm scientists in oncology and pathology with the quantitative information they need in their research to improve the cancer care process,” said Indica CEO Steven Hashagen. “By incorporating the high-quality innovation of Philips’ digital imaging and our precision HALO analysis platform, they have the tools to further investigate the predictive response of certain therapy with the ultimate goal to provide a personalized cancer treatment plan.”

Philips research customers now have access to a flexible investigational toolset to develop new solutions, as well as a suite of software features for evaluating such cases as HER2, ER, PR and Ki-67. Philips offers Indica’s HALO™ as an option with its Digital Pathology Solution for Research Use Only (RUO).

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 115,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Indica Labs, Inc.
Indica Labs provides software for quantitative evaluation of pathology images. Indica’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability. Indica’s broad range of industry leading tissue-specific image analysis algorithms can be used in a variety of truly integrated digital pathology environments, allowing pharmaceutical, healthcare, and research organizations worldwide to apply high-throughput image quantification in areas such as neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com or contact info@indicalab.com

Source: Indica Labs and Philips